Bladder cancer diagnostics play a pivotal role in early disease detection and treatment. Their applications encompass non-invasive screening through urine tests, imaging techniques such as cystoscopy, and advanced molecular assays. Benefits of bladder cancer diagnostics include timely detection of malignancies, enabling prompt intervention for better outcomes. These diagnostics feature high sensitivity and specificity, reducing the chances of false positives or negatives. They offer minimally invasive procedures, enhancing patient comfort. Additionally, they aid in monitoring treatment efficacy, ensuring personalized care for bladder cancer patients, and ultimately improving their quality of life and prognosis.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/global-bladder-cancer-diagnostics-market
Data Bridge Market Research analyses that the Global Bladder Cancer Diagnostics Market which was USD 2,076.41 million in 2022, is expected to reach USD 3,900.60 million by 2030 and is expected to undergo a CAGR of 8.2% during the forecast period of 2023-2030. Advancements in bladder cancer treatments, such as immunotherapies and targeted therapies, underscore the importance of precise diagnostics. Accurate diagnostic tools enable healthcare professionals to tailor treatment plans, optimizing therapeutic effectiveness and patient outcomes while minimizing potential side effects.
Key Findings of the Study
The aging population is expected to drive the market's growth rate
As the global population continues to age, there is a heightened risk of bladder cancer, a disease more prevalent in older individuals. This demographic shift increases the overall incidence of bladder cancer cases. Age-related factors, such as prolonged exposure to carcinogens and genetic predisposition, contribute to this trend, emphasizing the importance of early and effective bladder cancer diagnostics and treatments in elderly populations.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test Type (Cystoscopy, Urine Lab Test, Biopsy, Imaging Test, and Others), Stages (Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, and Other Cancer Types), End User (Hospital, Diagnostic Imaging Centers, Cancer Research Institutes, Independent Diagnostic Laboratories, and Associated Labs), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), FUJIFILM Corporation (Japan), CANON MEDICAL SYSTEMS CORPORATION (Japan), Siemens Healthcare GmbH (Germany), BD (Becton, Dickinson and Company) (U.S.), Illumina, Inc. (U.S.), Neusoft Corporation (China), Abbott (U.S.), General Electric Company (U.S.), Hologic Inc. (U.S.), QIAGEN (Germany), Cepheid (U.S.), Ambu A/S (Denmark), Time Medical Holding (China), MinFound Medical Systems Co., Ltd. (China)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export analysis, pricing analysis, production consumption analysis, and pestle analysis.
|
Segment Analysis:
The global bladder cancer diagnostics market is segmented into five notable segments based test type, stages, cancer type, end user, and distribution channel.
- On the basis of test type, the market is segmented into cystoscopy, urine lab test, biopsy, imaging test, and others.
- On the basis of stages, the market is segmented into stage I, stage II, stage III, and stage IV.
- On the basis of cancer type, the market is segmented into transitional cell bladder cancer, squamous cell bladder cancer, and other cancer types.
- On the basis of end user, the market is segmented into hospital, diagnostic imaging centers, cancer research institutes, independent diagnostic laboratories, and associated labs.
- On the basis of distribution channel, the market is segmented into direct tender and retail sales.
Major Players
Data Bridge Market Research recognizes the following companies as the global bladder cancer diagnostics market players in global bladder cancer diagnostics market are F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), FUJIFILM Corporation (Japan), CANON MEDICAL SYSTEMS CORPORATION (Japan), Siemens Healthcare GmbH (Germany).
Market Developments
- In May 2020, F. Hoffmann-La Roche Ltd completed its acquisition of Stratos Genomics. This strategic move allowed Roche to enter the DNA-based sequencing sector for diagnostic purposes. This expansion has significantly strengthened Roche's healthcare diagnosis division, positioning it for increased revenue generation. The acquisition enhances Roche's capabilities in the rapidly evolving field of genomics, enabling the development of advanced diagnostic solutions and contributing to the company's growth and innovation in healthcare.
- In January 2023, Thermo Fisher Scientific Inc. successfully finalized its acquisition of The Binding Site Group, a prominent player in the specialty diagnostics field. This strategic move is set to bolster Thermo Fisher's presence in specialty diagnostics, facilitating the development of advanced diagnostic solutions. The acquisition aligns with Thermo Fisher's commitment to innovation and enhances its capabilities in serving the evolving healthcare diagnostics market, ultimately contributing to the growth of the specialty diagnostics segment.
Regional Analysis
Geographically, the countries covered in the major global bladder cancer diagnostics market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa.
As per Data Bridge Market Research analysis:
North America dominates global bladder cancer diagnostics market during the forecast period 2023 - 2030
North America holds a significant share in the global bladder cancer diagnostics market, primarily due to the presence of key industry players such as F. Hoffmann-La Roche Ltd, Merck KGaA, Thermo Fisher Scientific Inc., Koninklijke Philips N.V., and Bio-Rad Laboratories, Inc. The region's market dominance is further bolstered by the increasing incidence of bladder cancer and advancements in imaging technologies, which are expected to drive substantial market growth throughout the forecast period.
For more detailed information about the global bladder cancer diagnostics market report, click here – https://www.databridgemarketresearch.com/de/reports/global-bladder-cancer-diagnostics-market
